ASCO_abstracts

Documents (3,155) JSON TSV

source DB	source ID	text	size	updated at	# proj.	updated_at
asco@alo33	170642	Background: We have previously shon the importance of utilizing the intact tissue section and quantitative multiplex immunofluorescence MIF for developing accurate prognostic risk models in prosta	2.11 KB	2023-01-16	1	2023-01-16
asco@alo33	170246	Background: Combination chemotherapy ith taxane and platinum, ith or ithout anthracycline, has been the standard first-line chemotherapy regime for metastatic endometrial cancer EC and there is no	2.22 KB	2023-01-16	1	2023-01-16
asco@alo33	168869	Background: Cancer patients pts are more than tice as likely to enter bankruptcy as the general US population. It is unknon ho often pts ith metastatic cancer are concerned about the financial tox	2.38 KB	2023-01-16	1	2023-01-16
asco@alo33	169185	Background: The PD-1Is pembrolizumab P and nivolumab N have demonstrated clinical activity in multiple tumor types. They can lead to unique immune related adverse events irAEs . Studies have sh	2.33 KB	2023-01-16	1	2023-01-16
asco@alo33	164600	Background: Young rectum presents a peculiar situation ith patients presenting ith adverse histologies and more advanced stage hen compared to older rectal cancer patients. Methods: We evaluated pat	2.13 KB	2023-01-16	1	2023-01-16
asco@alo33	168319	Background: Pembrolizumab is a PDL1 inhibitor licensed for the treatment of unresectable melanoma at a dose of 2mgkg every three eeks. A population pharmacokinetic model based on to compartment firs	2.27 KB	2023-01-16	1	2023-01-16
asco@alo33	168771	Background: Studies of immune checkpoint inhibitors e.g., anti-PD-1PD-L1 antibodies in ovarian cancer have demonstrated isolated responses in tumors ith clear cell histology. In order to assess th	2.19 KB	2023-01-16	1	2023-01-16
asco@alo33	171551	Background: ARMS is considered to be one of the most aggressive pediatric malignancies. Adults ith ARMS notoriously experience inferior outcomes. Our goal as to define our adult population ith ARMS	2.36 KB	2023-01-16	1	2023-01-16
asco@alo33	166849	Background: In-clinic application of Randomized Controlled Trial RCT results is complex. There is variability in conclusions of RCTs studying similar therapies and it is difficult to estimate thei	2.24 KB	2023-01-16	1	2023-01-16
asco@alo33	170652	Background: Success of immune checkpoint blockade therapy relies on the increase of effector T cells and decrease of regulatory T cells in the tumor microenvironment. Hoever, the underlying mechanis	2.13 KB	2023-01-16	1	2023-01-16